BCL2 and diffuse large B-cell lymphoma: Focusing on germinal center B cell-type DLBCL encompassing a considerable number of cases with genetic alterations affecting BCL2 family members revealed a trend toward PFS improvement using obinutuzumab (Vitolo et al., 2017; Schmitz et al., 2018).